The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...

Crispr Therapeutics (CRSP) quickly rose 1.3% amid some takeover speculation. Crispr (CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert ...

Study shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types.

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Outcomes validate the company’s PTAP platform as a foundation for a rapid, adaptable antiviral modality across animal and ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

A Swiss biotechnology company said it has used the gene-editing technology CRISPR to treat a patient with a dangerous blood disease called beta thalassemia, marking the technology’s first trial run by ...

Ecuadorian scientists are developing a biotechnological strategy to stop banana wilt by genetically editing the causative ...

CRISPR Therapeutics has significantly lagged the market in recent years due to several factors. However, the biotech has what it takes to be successful in the challenging gene-editing niche. This ...